April 4, 2018 / 5:36 AM / in 21 days

BRIEF-Thrombogenics Reports Initial Data From THR-317 Clinical Study

April 4 (Reuters) - THROMBOGENICS NV:

* CLINICAL TRIAL IS TARGETED TO BE INITIATED IN Q2 2018

* ‍STUDY ENROLLED A TOTAL OF 49 PATIENTS, INCLUDED ANTI-VEGF NAÏVE PATIENTS AND AS SUB-OPTIMAL ANTI-VEGF RESPONDERS​

* ‍THR-317 WAS SAFE AND WELL TOLERATED​

* ‍NO DOSE-LIMITING TOXICITIES OR RELEVANT SAFETY EVENTS WERE REPORTED AT ANY DOSE LEVEL​

* ‍DATA SUPPORT INITIATION OF A NEXT STUDY EVALUATING THR-317 IN COMBINATION WITH AN ANTI- VEGF​

* ‍30% ANTI-VEGF TREATMENT NAÏVE 8MG GROUP SUBJECTS SHOWED A > OR EQUAL TO 15 LETTER GAIN FROM BASELINE

* 5.3% ANTI-VEGF TREATMENT NAÏVE 4MG GROUP SUBJECTS SHOWED A > OR EQUAL TO 15 LETTER GAIN FROM BASELINE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below